Pharmafile Logo
Pharmafocus logo
Advanced Search

Press release

Showing 15 posts of 535 posts found.

New data suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

March 20, 2023
Business Services

STEVENAGE, UK, March 20, 2023 – New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in …

News
Press release

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

March 20, 2023
Business Services

Basel, March 20, 2023 — Novartis today presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), …

News
Press release

Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia

March 20, 2023
Business Services

Milan, Italy, March 20, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.

News
Press release

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer

March 17, 2023
Business Services

Addlestone UK, 17 March, 2023 –Astellas Pharma Ltd. (“Astellas”) today announced positive topline results from the Phase 3 EMBARK trial …

News
Press release

Newron to present at the 31st European Congress of Psychiatry

March 17, 2023
Business Services

Milan, Italy, March 17, 2023, 7am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused …

News
Press release

iOnctura announces publication of pioneering research describing the unique biological features of roginolisib

March 16, 2023
Business Services

Geneva, Switzerland and Amsterdam, The Netherlands, 16 March – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients …

News
Press release

PHARMANOVIA ENTERS INTO AN EXCLUSIVE LICENSING AGREEMENT WITH AETERNA ZENTARIS FOR THE FIRST AND ONLY ORALLY ADMINISTERED APPROVED MEDICINE FOR THE DIAGNOSIS OF GROWTH HORMONE DEFICIENCY IN ADULTS

March 16, 2023
Business Services

BASILDON, UK, 16 MARCH 2023 Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the …

News
Press release

Zolgensma®▼ (onasemnogene abeparvovec) receives NICE final draft guidance in presymptomatic babies up to 12 months with spinal muscular atrophy (SMA)

March 16, 2023
Business Services

 London, UK, 16th March 2023 – Novartis Gene Therapies has confirmed that the National Institute for Health and Care Excellence …

News
Press release

Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology

March 16, 2023
Business Services

Boston, Massachusetts, March 16th, 2023 – Aldena Therapeutics Inc. (Aldena) a private biotech company pioneering siRNA-based therapies for dermatological indications, …

News
Press release

Optibrium and PostEra Collaborate to Integrate AI Drug Discovery Solutions

March 15, 2023
Business Services

 

News
Press release

DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine

March 15, 2023
Business Services

Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that …

News
Press release

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

March 14, 2023
Business Services

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 14, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that, further …

News
Press release

Synaffix Announces Expansion of ADC Collaboration with MacroGenics

March 14, 2023
Business Services

AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the …

News
Press release

Acesion Pharma announces positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint achieved

March 14, 2023
Business Services

14 March 2023, Copenhagen, Denmark – Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the …

News
Press release

EP0042 receives Orphan Drug Designation from the US Food and Drug Administration

March 14, 2023
Business Services

 Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an …

News
Press release

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024